Deal covers use of sirolimus in ocular indications.



Santen Pharmaceutical obtained rights to MacuSight’s sirolimus for ocular diseases and conditions in Japan and Asia for $50 million. Wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) are among the conditions covered under the agreement.


Besides the upfront payment, MacuSight will receive milestone fees and royalties. MacuSight retains development and commercialization rights to sirolimus in all other markets.


Sirolimus, originally known as rapamycin, is a highly potent, broad-acting compound that has demonstrated the ability to combat a broad range of diseases and conditions, according to the companies. MacuSight is presently initiating a Phase II trial of sirolimus in DME and preparing to initiate a Phase II study in wet AMD later this year.








This site uses Akismet to reduce spam. Learn how your comment data is processed.